EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 3.0

Unraveling the Impact of Sarcopenia-Induced Lymphopenia on Treatment Response and Prognosis in Patients with Stage III Non–Small Cell Lung Cancer: Insights for Optimizing Chemoradiation and Immune Checkpoint Inhibitor

Joongyo Lee, Kyung Hwan Kim, Jina Kim, Chang Geol Lee, Jaeho Cho, Hong In Yoon, Yeona Cho

Cancer Research and Treatment · 2025

DOI: 10.4143/crt.2024.493 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Research and Treatment, 2025. Verfasst von Joongyo Lee und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Korea. Hauptthemen laut MEDLINE: Sarcopenia, Carcinoma, Non-Small-Cell Lung, Lymphopenia, Immune Checkpoint Inhibitors. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0). Gefördert von: Yonsei University College of Medicine, National Research Foundation of Korea.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Sarcopenia is a poor prognostic factor in non–small cell lung cancer (NSCLC). However, its prognostic significance in patients with NSCLC receiving immune checkpoint inhibitors (ICIs) and its relationship with lymphopenia remain unclear. We aimed to investigate the prognostic role of sarcopenia and its effect on lymphocyte recovery in patients with stage III NSCLC treated with concurrent chemoradiotherapy (CCRT) followed by ICI.Materials and Methods We retrospectively evaluated 151 patients with stage III NSCLC who received definitive CCRT followed by maintenance ICI between January 2016 and June 2022. Sarcopenia was evaluated by measuring the skeletal muscle area at the L3 vertebra level using computed tomography scans. Lymphocyte level changes were assessed based on measurements taken before and during CCRT and at 1, 2, 3, 6, and 12 months post-CCRT completion.

Results

Even after adjusting for baseline absolute lymphocyte count through propensity score-matching, patients with pre-radiotherapy (RT) sarcopenia (n=86) exhibited poor lymphocyte recovery and a significantly high incidence of grade ≥ 3 lymphopenia during CCRT. Pre-RT sarcopenia and grade ≥ 3 lymphopenia during CCRT emerged as prognostic factors for overall survival and progression-free survival, respectively. Concurrent chemotherapy dose adjustments, objective response after CCRT, and discontinuation of maintenance ICI were also analyzed as independent prognostic factors.

Conclusion

Our results demonstrated an association between pre-RT sarcopenia and poor survival, concurrent chemotherapy dose adjustments, and impaired lymphocyte recovery after definitive CCRT. Moreover, CCRT-induced lymphopenia not only contributed to poor prognosis but may have also impaired the therapeutic efficacy of subsequent maintenance ICI, ultimately worsening treatment outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SarcopeniaCarcinoma, Non-Small-Cell LungLymphopeniaImmune Checkpoint InhibitorsLung NeoplasmsChemoradiotherapyHumansMaleFemaleMiddle AgedPrognosisAgedRetrospective StudiesNeoplasm StagingTreatment OutcomeAdultAged, 80 and over

Stichwörter der Autor:innen

Immune checkpoint inhibitorsLymphopeniaNon-small-cell lung carcinomaRadiotherapySarcopenia

Substanzen

Immune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Department of Radiation Oncology, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Korea.
  • Department of Radiation Oncology, Gil Medical Center, Gachon University College of Medicine, Incheon, Korea.
  • Department of Radiation Oncology, Yonsei Cancer Center, Heavy Ion Therapy Research Institute, Yonsei University College of Medicine, Seoul, Korea.

Förderung

  • Yonsei University College of Medicine
  • National Research Foundation of Korea

Zitieren

APA

Lee, J., Kim, K. H., Kim, J., Lee, C. G., Cho, J., Yoon, H. I., & Cho, Y. (2025). Unraveling the Impact of Sarcopenia-Induced Lymphopenia on Treatment Response and Prognosis in Patients with Stage III Non–Small Cell Lung Cancer: Insights for Optimizing Chemoradiation and Immune Checkpoint Inhibitor. Cancer Research and Treatment. https://doi.org/10.4143/crt.2024.493

Vancouver

Lee J, Kim KH, Kim J, Lee CG, Cho J, Yoon HI, et al. Unraveling the Impact of Sarcopenia-Induced Lymphopenia on Treatment Response and Prognosis in Patients with Stage III Non–Small Cell Lung Cancer: Insights for Optimizing Chemoradiation and Immune Checkpoint Inhibitor. Cancer Research and Treatment. 2025. doi:10.4143/crt.2024.493

BibTeX
@article{Lee2025,
  author = {Lee, Joongyo and Kim, Kyung Hwan and Kim, Jina and Lee, Chang Geol and Cho, Jaeho and Yoon, Hong In and Cho, Yeona},
  title = {Unraveling the Impact of Sarcopenia-Induced Lymphopenia on Treatment Response and Prognosis in Patients with Stage III Non–Small Cell Lung Cancer: Insights for Optimizing Chemoradiation and Immune Checkpoint Inhibitor},
  journal = {Cancer Research and Treatment},
  year = {2025},
  doi = {10.4143/crt.2024.493}
}
Kostenlos starten →